Menu Search
Equities

Sartorius Stedim Biotech SA

DIMp:EBT

Sartorius Stedim Biotech SA

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Sartorius Stedim Biotech SA's revenues fell -20.53% from 3.49bn to 2.78bn. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from 876.10m to 309.70m, a -64.65% decrease.
Gross margin41.82%
Net profit margin6.31%
Operating margin14.43%
Return on assets2.61%
Return on equity5.24%
Return on investment3.04%
More ▼

Cash flow in EURView more

In 2023, Sartorius Stedim Biotech SA increased its cash reserves by 8.87%, or 9.50m. Cash Flow from Financing totalled 1.99bn or 71.56% of revenues. In addition the company generated 746.40m in cash from operations while cash used for investing totalled 2.72bn.
Cash flow per share4.86
Price/Cash flow per share37.30
Book value per share39.95
Tangible book value per share-6.88
More ▼

Balance sheet in EURView more

Sartorius Stedim Biotech SA has a Debt to Total Capital ratio of 42.66%, a lower figure than the previous year's 51.83%.
Current ratio1.94
Quick ratio1.03
Total debt/total equity0.7507
Total debt/total capital0.4266
More ▼

Growth rates in EUR

SmartText is unavailable
Div yield(5 year avg)0.30%
Div growth rate (5 year)3.90%
Payout ratio (TTM)37.59%
EPS growth(5 years)8.29
EPS (TTM) vs
TTM 1 year ago		-74.02
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.